The Securities and Exchange Commission has concluded its investigation into Illumina’s 2021 acquisition of liquid biopsy maker Grail and recommended no enforcement action be taken, the company said. Illumina bought Grail back after it had first spun off the business in 2016. But regulators objected to the move, warning Illumina’s dominance in the sequencing market would deter development of rival multi-cancer early detection tests. Last year, Illumina avoided a 432 million euro fine from the European Commission after the Court of Justice ruled the EC did not have the authority to investigate the Grail acquisition. The U.S. Federal Trade Commission also dismissed its case against Illumina and Grail after the spinoff.
Read the full article: SEC Ends Probe of Illumina’s Grail Acquisition //
Source: https://www.medtechdive.com/news/Illumina-SEC-ends-Grail-investigation-Q1/747691/